300639.SZ
凯普生物
SZSE · Healthcare · C 制造业 · CN
CNY 5.97
−3.40%Year over year
Reported trailing growth
- Revenue
- -13.7%
- EBITDA
- —
- EBIT
- +85.7%
- EPS
- +84.0%
- Free cash flow
- +224.2%
- Operating cash flow
- +68.5%
Forward estimates
Based on analyst estimates
- Revenue
- +96.3%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -50.7%
- EBITDA
- -81.5%
- EBIT
- +81.0%
- Net income
- +80.0%
- EPS
- +79.4%
- Free cash flow
- -24.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026